down syndrome screening risk calculation software

First-trimester maternal serum placental growth factor level.

First-trimester maternal serum anti-Mullerian hormone level.

First-trimester maternal serum A disintegrin and metalloprotease 12 (ADAM12-S) level.

First-trimester maternal plasma levels of follistatin-related gene protein.First-trimester ultrasound assessment of the nasal bone.First-trimester serum analyte testing (hCG footnotes* and PAPP-A) alone without NT measurement.

First-trimester NT measurement alone (without first-trimester serum analyte testing) in the absence of fetal cystic hygroma in singleton pregnancies.See CPB 0464 - Serum and Urine Marker Screening for Fetal Aneuploidy and CPB 0787 Comparative Genomic Hybridization (CGH).Īetna considers other noninvasive screening schemes for fetal aneuploidy to be experimental and investigational, including the following because their effectiveness has not been established: Measurement of cell-free fetal nucleic acids in maternal blood when criteria are met in CPB 0464 - Serum and Urine Marker Screening for Fetal Aneuploidy.Īetna considers the above-listed screening tests for fetal aneuploidy not medically necessary for women who have previously had a microarray or non-invasive prenatal testing (NIPT) with cell-free DNA during the current pregnancy.Serum integrated screening for pregnancies where NT measurement is not available or can not be obtained: First-trimester (PAPP-A plus hCG footnotes*) plus second-trimester quad (MSAFP, uncongugated estriol, inhibin A, and hCG footnotes*) screening or.Second-trimester serum analyte screening (see CPB 0464 - Serum and Urine Marker Screening for Fetal Aneuploidy) or.Integrated, sequential, or contingent screening: First-trimester triple test (NT, PAPP-A, and hCG footnotes*) plus second-trimester quadruple test (maternal serum alfa-fetoprotein (MSAFP, unconjugated estriol, inhibin A, and hCG footnotes*) screening or.First-trimester NT measurements results combined with the results of first trimester serum analyte tests that include pregnancy-associated plasma protein A (PAPP-A) plus beta-human chorionic gonadotropin (hCG) footnotes* or.First-trimester nuchal translucency (NT) testing alone (without serum analyte screening) for multiple gestations or.Aetna considers the following noninvasive screening schemes for fetal aneuploidy medically necessary:

Down syndrome screening risk calculation software